Vedolizumab (Entyvio; Takeda), an integrin receptor antagonist, was found to be superior to adalimumab (Humira; AbbVie), a tumor necrosis factor-alpha (TNFα) antagonist, in achieving clinical remission in patients with moderately to severely active ulcerative colitis (UC), according to results from a phase 3b head-to-head trial.
Peppermint oil (PO) was found to be safe and effective in treating pain and global symptoms associated with irritable bowel syndrome (IBS) in adult patients, according to the results of a recently published systematic review and meta-analysis.
In older patients with inflammatory bowel disease (IBD), tumor necrosis factor alpha antagonist (anti-TNF) therapy and vedolizumab (an integrin receptor antagonist) were found to be comparable with regard to both safety and effectiveness, according to a study published in Alimentary Pharmacology & Therapeutics.
Results of a recently published trial suggested pregabalin, a calcium channel alpha-2 delta ligand, may reduce gastrointestinal symptoms of irritable bowel syndrome.
Only 42.6 percent of 84 patients with biopsy-proven advanced colorectal polyps were taking aspirin
To investigate the association between this diabetes drug class and IBD risk, the study authors searched various databases for controlled clinical trials and observational studies involving DPP-4 inhibitors where IBD events were reported.
The American Gastroenterological Association (AGA) report, Inflammatory Bowel Disease (IBD) in Pregnancy Clinical Care Pathway, was published online January 15 in Gastroenterology.
In order to assess the safety of biologic agents in older patients, the authors utilized PubMed/Medline and Embase to search for studies conducted in older patients with inflammatory bowel disease, rheumatoid arthritis, or psoriasis.
Over time, the prevalence of gastroschisis has increased, with more babies born with gastroschisis in areas with high and medium vs low opioid prescription rates, according to new research.
The Company has already completed a Phase 1 trial of this synthetic glucagon-like peptide (GLP-2) analog.
